Evolvere BioSciences
Making Next-Generation Antibiotics that Outpace Bacterial Evolution
Evolvere BioSciences is active in the healthcare space based in Oxford, England, United Kingdom.
Profile
🦠🤖 We use our computational models to make next-generation antibiotics that outcompete bacterial evolution and precisely target pathogenic bacteria, without harming good microbes or human cells.
☠️ Current antibiotics stop working because bacteria evolve resistance to them. This makes drug-resistant bacteria a looming global health crisis - already killing more people than malaria and AIDS and it is getting exponentially worse 📈.
🧬 Our approach leverages co-evolutionary protein-protein interaction datasets combined with AI to forecast bacterial mutations and create ‘future-proof’ antibiotics, addressing antibiotic resistance before it develops. This changes the game for how frequently society will need to make new antibiotics and how long our new antibiotics will be able to treat patients 👩⚕️.
We are a team of biochemists and evolutionary biologists who met at the University of Oxford.
Within the healthcare space, the company focuses on its core offering rather than a broad product line.
Oxford, England, United Kingdom is where the company is located.
The company is listed at the Summer 2024 stage of development.
The company reports a headcount in the 3 range.
Directory analysis
Evolvere BioSciences develops next‑generation antibiotics that anticipate bacterial evolution, using AI‑driven computational models and co‑evolutionary protein‑protein interaction data. The company designs drugs that target pathogenic bacteria while sparing beneficial microbes and human cells, aiming to create ‘future‑proof’ antibiotics that remain effective longer than conventional drugs.
Positioning: Evolvere positions itself at the intersection of computational biology and antimicrobial drug discovery, targeting the growing global threat of antibiotic resistance. With a small team and early‑stage status, its technology is still in development, but it could offer a differentiated solution in a market that urgently needs new antibiotics.
Note: Evolvere is a UK‑based startup focused on AI‑driven, evolution‑resistant antibiotics.
Auto-generated directory analysis from public data · updated 12 Oct 2026. Informational only, not investment advice.
| Sector | Healthcare |
|---|---|
| Headquarters | Oxford, England, United Kingdom |
| Country | United Kingdom |
| Employees | 3 |
| Stage | Summer 2024 |
Website: www.evolverebiosciences.com
Browse related
Create a free account